BACKGROUND: Pertussis serodiagnosis is increasingly being used in the United States despite the lack of a US Food and Drug Administration-approved, commercially available assay. To better understand the utility of these assays in diagnosing pertussis, serology assays were evaluated for analytical parameters and clinical accuracy. METHODS: Forty-three antigen-antibody combinations were evaluated for single-point diagnosis of pertussis. Serum panels included sera from laboratory-confirmed cases, an international reference standard, and healthy donors. Phase I panel (n = 20) of sera was used to assess precision, linearity, and accuracy; Phase II panel (n = 226) followed with positive percent agreement (PPA) and negative percent agreement (NPA) estimates. Analytical analyses included coefficients of variation (CV) and concordance correlation coefficients (rc). RESULTS: Intra-analyst variability was found to be relatively low among samples per assay, with only 6% (78 of 1240) having CV >20%, primarily with the highly concentrated immunoglobulin (Ig)G anti-pertussis toxin (PT) specimens and IgM assays. The rc measurements to assess linearity ranged between 0.282 and 0.994, 0.332 and 0.999, and -0.056 and 0.482 for IgA, IgG, and IgM, respectively. Analytical accuracy for calibrated IgG anti-PT assays was 86%-115%. The PPA and NPA varied greatly for all assays; PPA/NPA ranges for IgA, IgG, and IgM assays, with culture and/or polymerase chain reaction positivity as control, were 29-90/13-100, 26-96/27-100, and 0-73/42-100, respectively. In IgG assays, mixing filamentous hemagglutinin antigen with PT increased PPA but decreased NPA. CONCLUSIONS: Seroassays varied substantially under both analytical and clinical parameters; however, those that were calibrated to a reference standard were highly accurate. Our findings support incorporation of calibrated pertussis seroassays to the pertussis case definition for improved diagnosis and surveillance. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
BACKGROUND: Pertussis serodiagnosis is increasingly being used in the United States despite the lack of a US Food and Drug Administration-approved, commercially available assay. To better understand the utility of these assays in diagnosing pertussis, serology assays were evaluated for analytical parameters and clinical accuracy. METHODS: Forty-three antigen-antibody combinations were evaluated for single-point diagnosis of pertussis. Serum panels included sera from laboratory-confirmed cases, an international reference standard, and healthy donors. Phase I panel (n = 20) of sera was used to assess precision, linearity, and accuracy; Phase II panel (n = 226) followed with positive percent agreement (PPA) and negative percent agreement (NPA) estimates. Analytical analyses included coefficients of variation (CV) and concordance correlation coefficients (rc). RESULTS: Intra-analyst variability was found to be relatively low among samples per assay, with only 6% (78 of 1240) having CV >20%, primarily with the highly concentrated immunoglobulin (Ig)G anti-pertussis toxin (PT) specimens and IgM assays. The rc measurements to assess linearity ranged between 0.282 and 0.994, 0.332 and 0.999, and -0.056 and 0.482 for IgA, IgG, and IgM, respectively. Analytical accuracy for calibrated IgG anti-PT assays was 86%-115%. The PPA and NPA varied greatly for all assays; PPA/NPA ranges for IgA, IgG, and IgM assays, with culture and/or polymerase chain reaction positivity as control, were 29-90/13-100, 26-96/27-100, and 0-73/42-100, respectively. In IgG assays, mixing filamentous hemagglutinin antigen with PT increased PPA but decreased NPA. CONCLUSIONS: Seroassays varied substantially under both analytical and clinical parameters; however, those that were calibrated to a reference standard were highly accurate. Our findings support incorporation of calibrated pertussis seroassays to the pertussis case definition for improved diagnosis and surveillance. Published by Oxford University Press on behalf of the Pediatric Infectious Diseases Society 2016. This work is written by (a) US Government employee(s) and is in the public domain in the US.
Authors: H E de Melker; F G Versteegh; M A Conyn-Van Spaendonck; L H Elvers; G A Berbers; A van Der Zee; J F Schellekens Journal: J Clin Microbiol Date: 2000-02 Impact factor: 5.948
Authors: Sandra L Menzies; Vijay Kadwad; Lucia C Pawloski; Tsai-Lien Lin; Andrew L Baughman; Monte Martin; Maria Lucia C Tondella; Bruce D Meade Journal: Clin Vaccine Immunol Date: 2009-10-28
Authors: Brunilís Burgos-Rivera; Adria D Lee; Katherine E Bowden; Amanda E Faulkner; Brent L Seaton; Bryndon D Lembke; Charles P Cartwright; Stacey W Martin; M Lucia Tondella Journal: J Clin Microbiol Date: 2015-03-25 Impact factor: 5.948
Authors: Stanley C Wei; Kathleen Tatti; Kimberly Cushing; Jennifer Rosen; Kristin Brown; Pamela Cassiday; Thomas Clark; Richard Olans; Lucia Pawloski; Monte Martin; Maria Lucia Tondella; Stacey W Martin Journal: Clin Infect Dis Date: 2010-08-01 Impact factor: 9.079
Authors: Aditi Kapasi; Bruce D Meade; Brian Plikaytis; Lucia Pawloski; Monte D Martin; Sandra Yoder; Michael T Rock; Séverine Coddens; Valérie Haezebroeck; Françoise Fievet-Groyne; Garvin Bixler; Charles Jones; Stephen Hildreth; Kathryn M Edwards; Nancy E Messonnier; Maria L Tondella Journal: Clin Vaccine Immunol Date: 2011-11-23
Authors: Marion Riffelmann; Martina Littmann; Christel Hülße; Wiebke Hellenbrand; Carl Heinz Wirsing von König Journal: Dtsch Arztebl Int Date: 2008-09-12 Impact factor: 5.594
Authors: N Guiso; G Berbers; N K Fry; Q He; M Riffelmann; C H Wirsing von König Journal: Eur J Clin Microbiol Infect Dis Date: 2010-11-11 Impact factor: 3.267
Authors: Adria D Lee; Pamela K Cassiday; Lucia C Pawloski; Kathleen M Tatti; Monte D Martin; Elizabeth C Briere; M Lucia Tondella; Stacey W Martin Journal: PLoS One Date: 2018-04-13 Impact factor: 3.240